Drug Profile
Glycerol phenylbutyrate - Horizon Therapeutics
Alternative Names: GT4P; HPN-100; RavictiLatest Information Update: 27 Mar 2024
Price :
$50
*
At a glance
- Originator Ucyclyd Pharma
- Developer Horizon Pharma; Horizon Therapeutics plc; Immedica; National Jewish Health; Winhealth Pharma
- Class Hepatoprotectants; Phenylbutyrates; Small molecules
- Mechanism of Action Ammonia scavengers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Inborn urea cycle disorders
- Phase I/II Cystic fibrosis
- Discontinued Hepatic encephalopathy
Most Recent Events
- 21 Mar 2024 Registered for Inborn urea cycle disorders (Adjunctive treatment) in Taiwan (PO)
- 23 Oct 2023 Glycerol phenylbutyrate - Horizon Therapeutics receives Orphan Drug status for Epilepsy in European Union
- 21 Jun 2023 Registered for Inborn urea cycle disorders (Adjunctive treatment) in China (PO)